Rocket Pharmaceuticals (RCKT) Liabilities and Shareholders Equity (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $285.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 39.41% year-over-year to $285.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (down 23.6% YoY), and the FY2025 full-year result was $330.4 million, down 37.38% from the prior year.
• Liabilities and Shareholders Equity eased to $285.4 million in Q1 2026, from $330.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $566.3 million in Q4 2023 to a low of $405000.0 in Q2 2022.
• A 5-year average of $286.5 million and a median of $368.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 75697.66% in 2022, while the deepest fall reached 70.95% in 2022.
• Tracing RCKT's Liabilities and Shareholders Equity over 5 years: stood at $551.8 million in 2022, then climbed by 2.63% to $566.3 million in 2023, then slipped by 6.82% to $527.7 million in 2024, then tumbled by 37.38% to $330.4 million in 2025, then retreated by 13.63% to $285.4 million in 2026.
• Business Quant data shows RCKT's Liabilities and Shareholders Equity at $285.4 million in Q1 2026, $330.4 million in Q4 2025, and $368.0 million in Q3 2025.